149 related articles for article (PubMed ID: 24048635)
21. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
[TBL] [Abstract][Full Text] [Related]
22. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.
Scaramucci L; Giovannini M; Niscola P; Tendas A; Perrotti A; De Fabritiis P
Blood Transfus; 2014 Oct; 12(4):605-7. PubMed ID: 25351191
[No Abstract] [Full Text] [Related]
23. Orphan disease gains second treatment option.
Morrow T
Manag Care; 2009 Jan; 18(1):47-9. PubMed ID: 19186672
[No Abstract] [Full Text] [Related]
24. Eltrombopag (Revolade ) and thrombocytopenia in patients with hepatitis C. Hepatotoxic drug; more harms than benefits.
Prescrire Int; 2015 Sep; 24(163):208-9. PubMed ID: 26417629
[TBL] [Abstract][Full Text] [Related]
25. Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis.
Polverelli N; Catani L; Sollazzo D; Vianelli N; Palandri F
Ann Hematol; 2015 Feb; 94(2):339-41. PubMed ID: 24994539
[No Abstract] [Full Text] [Related]
26. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
Maroun MC; Ososki R; Andersen JC; Dhar JP
Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
[TBL] [Abstract][Full Text] [Related]
27. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
Alvarez Román MT; Fernández Bello I; Arias-Salgado EG; Rivas Pollmar MI; Jiménez Yuste V; Martín Salces M; Butta NV
Thromb Haemost; 2014 Jul; 112(1):65-72. PubMed ID: 24500066
[TBL] [Abstract][Full Text] [Related]
28. [Development of chronic myelogenous leukemia during treatment with TPO receptor agonist for ITP].
Hattori H; Kuwayama M; Takamori H; Nishiura N; Karasuno T
Rinsho Ketsueki; 2014 Dec; 55(12):2429-32. PubMed ID: 25744045
[TBL] [Abstract][Full Text] [Related]
29. Thrombosis of a Left Atrial Appendage Occluder After Treatment With Thrombopoietin Receptor Agonists.
Cubero-Gallego H; Romaguera R; Teruel L; Gomez-Lara J; Berdejo J; Gomez-Hospital JA; Cequier A
JACC Cardiovasc Interv; 2018 Jan; 11(2):e15-e16. PubMed ID: 29289629
[No Abstract] [Full Text] [Related]
30. Severe cutaneous toxicity related to Eltrombopag.
Meyer SC; Rovó A; Tsakiris DA; Scherer K; Tichelli A; Holbro A
Br J Haematol; 2013 Feb; 160(3):412-4. PubMed ID: 23151239
[No Abstract] [Full Text] [Related]
31. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
Meyer O; Salama A
Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379
[TBL] [Abstract][Full Text] [Related]
32. Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction.
Gunes H; Kivrak T
Curr Drug Saf; 2016; 11(2):174-6. PubMed ID: 26560493
[TBL] [Abstract][Full Text] [Related]
33. Acute renal failure in a patient with antiphospholipid syndrome and immune thrombocytopenic purpura treated with eltrombopag.
Sperati CJ; Streiff MB
Am J Hematol; 2010 Sep; 85(9):724-6. PubMed ID: 20652968
[TBL] [Abstract][Full Text] [Related]
34. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
González-López TJ; Pascual C; Álvarez-Román MT; Fernández-Fuertes F; Sánchez-González B; Caparrós I; Jarque I; Mingot-Castellano ME; Hernández-Rivas JA; Martín-Salces M; Solán L; Beneit P; Jiménez R; Bernat S; Andrade MM; Cortés M; Cortti MJ; Pérez-Crespo S; Gómez-Núñez M; Olivera PE; Pérez-Rus G; Martínez-Robles V; Alonso R; Fernández-Rodríguez A; Arratibel MC; Perera M; Fernández-Miñano C; Fuertes-Palacio MA; Vázquez-Paganini JA; Gutierrez-Jomarrón I; Valcarce I; de Cabo E; Sainz A; Fisac R; Aguilar C; Paz Martínez-Badas M; Peñarrubia MJ; Calbacho M; de Cos C; González-Silva M; Coria E; Alonso A; Casaus A; Luaña A; Galán P; Fernández-Canal C; Garcia-Frade J; González-Porras JR
Am J Hematol; 2015 Mar; 90(3):E40-3. PubMed ID: 25400215
[TBL] [Abstract][Full Text] [Related]
35. Eltrombopag-associated hyperpigmentation.
Braunstein I; Wanat KA; Elenitsas R; Xu X; Frey N; Rosenbach M
JAMA Dermatol; 2013 Sep; 149(9):1112-5. PubMed ID: 23884150
[No Abstract] [Full Text] [Related]
36. Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).
Bussel JB; Saleh MN; Vasey SY; Mayer B; Arning M; Stone NL
Br J Haematol; 2013 Feb; 160(4):538-46. PubMed ID: 23278590
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.
González-López TJ; Fernández-Fuertes F; Hernández-Rivas JA; Sánchez-González B; Martínez-Robles V; Alvarez-Román MT; Pérez-Rus G; Pascual C; Bernat S; Arrieta-Cerdán E; Aguilar C; Bárez A; Peñarrubia MJ; Olivera P; Fernández-Rodríguez A; de Cabo E; García-Frade LJ; González-Porras JR
Int J Hematol; 2017 Oct; 106(4):508-516. PubMed ID: 28667351
[TBL] [Abstract][Full Text] [Related]
38. Eltrombopag in chronic idiopathic thrombocytopenic purpura.
Panzer S; Pabinger I
Lancet; 2009 Feb; 373(9664):607-8. PubMed ID: 19231614
[No Abstract] [Full Text] [Related]
39. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.
Williams DD; Peng B; Bailey CK; Wire MB; Deng Y; Park JW; Collins DA; Kapsi SG; Jenkins JM
Clin Ther; 2009 Apr; 31(4):764-76. PubMed ID: 19446149
[TBL] [Abstract][Full Text] [Related]
40. Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia.
González-López TJ; Sánchez-González B; Pascual C; Arefi M; de Cabo E; Alonso A; Martín-Salces M; Jiménez-Bárcenas R; Calbacho M; Galan P; Barez A; González-Porras JR
Platelets; 2015; 26(1):83-6. PubMed ID: 24499036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
